Anemia secondary to chemo and/or radiotherapy.
Conditions
Interventions
EPOCIM(EPO):600 IU/kg (intravenous route) single weekly dose,or 150 IU/kg(subcutaneously),3 times a week, managing a maximum of 40 000 UI/week for 8 weeks .
Sponsors
Center of Molecular Immunology(CIM)
No proceed
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.Patients that fulfill with diagnostic criteria. 2.Patients with cytological and/or histological diagnosis of cancer of any localization that are receiving chemotherapy and/or radiotherapy. 3.Patients whose parents or tutors granted written consent for participation in the study. 4.Patients aged between 1 and 18 years.
Exclusion criteria
Exclusion criteria: 1.Patients with known hypersensitivity to products derived from mammalian cells or hypersensitivity to human albumin. 2.Patients pregnant or breastfeeding. 3.Patients with active hemorrhage or hemolysis. 4.Patients with non-controlled arterial hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Value of Hemoglobin in g / l at the beginning of treatment and at the 8th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time of the hemoglobin values(g/l). Measurement time:8 weeks. occurrence of any adverse event in the subject,intensity of adverse events,adverse events description. Measurement time:8 weeks. Number of transfusions received during the previous 2 months and weekly during treatment. | — |
Countries
Cuba
Contacts
Public ContactMD.Giselle Saurez
CIMAB S.A
Outcome results
None listed